Trial Profile
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Hormone and Docetaxel Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs SGI 1776 (Primary)
- Indications Adenocarcinoma; Non-Hodgkin's lymphoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Astex Pharmaceuticals
- 11 Nov 2010 According to a SuperGen media release, the development of SGI 1776 has been dicontinued due to adverse events.
- 20 Oct 2010 Planned end date changed from 1 Jul 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 19 Feb 2009 New source identified ana integrated (ClinicalTrials.gov record NCT00848601). Status changed from not yet recruiting to recruiting. Start and end dates, patient number and lead centres/investigators added.